초록 ▼

The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active a

The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.

대표청구항 ▼

1. A method of reducing a symptom associated with an abrupt reduction in an endogenous or exogenous chemical in a subject, the method comprising: (a) vaginally administering to the subject a single administration of a single dosage form comprising an active agent, wherein the release rate of the act

1. A method of reducing a symptom associated with an abrupt reduction in an endogenous or exogenous chemical in a subject, the method comprising: (a) vaginally administering to the subject a single administration of a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and(b) removing the single dosage form from the subject after the release rate of the active agent is at or below a terminal symptom threshold level. 2. The method of claim 1, wherein the single dosage form is administered to the subject for about one week to about one year. 3. The method of claim 1, wherein the single dosage form is administered to the subject for about at least three days. 4. The method of claim 1, wherein the symptom is associated with menopause. 5. The method of claim 1, wherein the active agent is a hormone. 6. The method of claim 5, wherein the hormone is selected from the group consisting of an estrogenic compound, a progestinic compound, an androgenic compound, a corticosteroid, and combinations thereof. 7. The method of claim 1, wherein the symptom is associated with withdrawal due to a cessation in the administration of an endogenous or exogenous chemical to the subject. 8. The method of any one of claim 7, wherein the active agent is selected from the group consisting of a stimulant, a beta-blocker, an opioid, an opioid antagonist, a benzodiazepine, a barbiturate, and a selective serotonin reuptake inhibitor (SSRI). 9. The method of claim 1, wherein the symptom is associated with an addiction to an exogenous chemical. 10. The method of claim 9, wherein the active agent is selected from the group consisting of nicotine, caffeine, and methadone. 11. The method of claim 1, wherein the single dosage form is selected from the group consisting of an intravaginal ring, an intrauterine dosage form, and a vaginal pessary. 12. The method of claim 1, wherein the single dosage form is an intravaginal ring. 13. The method of claim 1, wherein the dosage form is an implant. 14. The method of claim 1, wherein the release rate of the active agent tapers linearly throughout the administration. 15. The method of claim 1, wherein the release rate of the active agent tapers biphasically throughout the administration. 16. The method of claim 1, wherein the release rate of the active agent tapers first order exponentially throughout the administration. 17. The method of claim 1, wherein the active agent is passively released from the single dosage form. 18. The method of claim 1, wherein the active agent is actively released from the single dosage form. 19. A therapeutic package comprising: (a) the single dosage form of claim 1; and(b) a label comprising directions for use of the single dosage form for reducing a symptom associated with the abrupt reduction in an endogenous or exogenous chemical in a subject.